Icon Plc (NASDAQ:ICLR) – Research analysts at KeyCorp reduced their Q1 2018 earnings per share (EPS) estimates for Icon in a report released on Tuesday. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings per share of $1.40 for the quarter, down from their prior estimate of $1.42. KeyCorp currently has a “Buy” rating and a $130.00 price target on the stock. KeyCorp also issued estimates for Icon’s Q3 2018 earnings at $1.55 EPS, Q4 2018 earnings at $1.61 EPS, FY2018 earnings at $6.02 EPS and FY2019 earnings at $6.98 EPS.
Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. ValuEngine lowered shares of Icon from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Jefferies Group increased their price objective on shares of Icon from $122.00 to $132.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Robert W. Baird reissued a “buy” rating and issued a $123.00 price objective on shares of Icon in a research report on Thursday, October 12th. Finally, Barclays increased their price objective on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Icon currently has a consensus rating of “Buy” and a consensus price target of $121.82.
Shares of Icon (NASDAQ ICLR) opened at $113.27 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. Icon has a 1 year low of $76.46 and a 1 year high of $124.48. The firm has a market cap of $6,120.00, a PE ratio of 21.99, a P/E/G ratio of 1.63 and a beta of 0.61.
Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.03. The firm had revenue of $440.30 million for the quarter, compared to analysts’ expectations of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.19 EPS.
A number of hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC grew its stake in Icon by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after acquiring an additional 24 shares in the last quarter. Bangor Savings Bank grew its stake in Icon by 1.4% in the 2nd quarter. Bangor Savings Bank now owns 11,539 shares of the medical research company’s stock worth $1,128,000 after acquiring an additional 161 shares in the last quarter. Acrospire Investment Management LLC grew its stake in Icon by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares in the last quarter. D.A. Davidson & CO. grew its stake in Icon by 7.8% in the 2nd quarter. D.A. Davidson & CO. now owns 4,761 shares of the medical research company’s stock worth $465,000 after acquiring an additional 345 shares in the last quarter. Finally, MML Investors Services LLC grew its stake in Icon by 9.0% in the 2nd quarter. MML Investors Services LLC now owns 4,983 shares of the medical research company’s stock worth $487,000 after acquiring an additional 413 shares in the last quarter. Institutional investors and hedge funds own 89.66% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Q1 2018 EPS Estimates for Icon Plc Reduced by Analyst (ICLR)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/q1-2018-eps-estimates-for-icon-plc-reduced-by-analyst-iclr.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.